BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,750,000 shares, a growth of 18.8% from the July 31st total of 4,000,000 shares. Based on an average trading volume of 955,100 shares, the days-to-cover ratio is presently 5.0 days.
BioAtla Stock Performance
Shares of BCAB stock traded down $0.05 on Friday, hitting $1.77. The company's stock had a trading volume of 457,341 shares, compared to its average volume of 723,595. BioAtla has a fifty-two week low of $1.14 and a fifty-two week high of $4.02. The stock's 50 day moving average is $1.63 and its 200-day moving average is $2.20. The company has a market capitalization of $85.17 million, a PE ratio of -0.71 and a beta of 1.06.
BioAtla (NASDAQ:BCAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the firm earned ($0.75) EPS. On average, research analysts forecast that BioAtla will post -1.6 earnings per share for the current year.
Institutional Trading of BioAtla
A number of institutional investors have recently modified their holdings of the stock. Ground Swell Capital LLC bought a new stake in shares of BioAtla during the 2nd quarter worth approximately $33,000. Valmark Advisers Inc. bought a new position in shares of BioAtla in the 2nd quarter valued at $34,000. Rinkey Investments bought a new stake in shares of BioAtla during the 2nd quarter worth $35,000. Price T Rowe Associates Inc. MD acquired a new stake in BioAtla in the first quarter valued at about $45,000. Finally, American Century Companies Inc. grew its position in BioAtla by 36.1% in the second quarter. American Century Companies Inc. now owns 43,391 shares of the company's stock valued at $59,000 after acquiring an additional 11,503 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
BCAB has been the topic of several research reports. JMP Securities decreased their price objective on shares of BioAtla from $12.00 to $5.00 and set a "market outperform" rating on the stock in a report on Thursday, May 23rd. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of BioAtla in a report on Wednesday, May 15th.
Check Out Our Latest Report on BCAB
BioAtla Company Profile
(
Get Free Report)
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
See Also
Before you consider BioAtla, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAtla wasn't on the list.
While BioAtla currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
